Alignment Healthcare 株価情報 (NASDAQ: ALHC)

最新ニュース Alignment Healthcare (NASDAQ:ALHC) 株価情報

Alignment Healthcare

Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.

Alignment Healthcare, Inc. - Common Stock

Alignment Healthcare Inc

Scotiabank analyst Mario Saric maintains Boardwalk REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BEI#TSX">BEI</a>) with a Sector Perform and lowers the price target from C$79.5 to C$78.5.

News

Price Target

Analyst Ratings

TSX:BEI

TSX:BEI/UN

Scotiabank Maintains Sector Perform on Boardwalk REIT, Lowers Price Target to C$78.5

Truist Securities analyst Mark Hughes initiates coverage on MSC Income Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSIF#NYSE">MSIF</a>) with a Buy rating and announces Price Target of $20.

Initiation

MSIF

Truist Securities Initiates Coverage On MSC Income Fund with Buy Rating, Announces Price Target of $20

<a href="https://www.secretstock.com/mkzr" title="https://www.secretstock.com/mkzr">https://www.secretstock.com/mkzr</a>

MKZR

Mackenzie Realty Capital Paid $225K For Marketing Services Including Two-Day Advertorial Starting February 24, 2025.

Citizens Capital Markets analyst Jonathan Wolleben reiterates Mirum Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRM#NASDAQ">MIRM</a>) with a Market Outperform and maintains $74 price target.

Reiteration

MIRM

Citizens Capital Markets Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $74 Price Target

Raymond James analyst Frank Louthan upgrades Uniti Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNIT#NASDAQ">UNIT</a>) from Outperform to Strong Buy and raises the price target from $6 to $8.

Upgrades

UNIT

Raymond James Upgrades Uniti Group to Strong Buy, Raises Price Target to $8

Raymond James analyst Robert Dodd initiates coverage on MSC Income Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSIF#NYSE">MSIF</a>) with a Market Perform rating.

Raymond James Initiates Coverage On MSC Income Fund with Market Perform Rating

For the second quarter of fiscal 2025, total revenues are expected to be between $675 million and $775 million, adjusted homebuilding gross margin is expected to be between 17.5% and 18.5%, adjusted income before income taxes is expected to be between $20 million and $30 million and adjusted EBITDA is expected to be between $50 million and $60 million.

Guidance

Hovnanian Enterprises Expects Q2 Revenue Of $675M-$775M Vs. $821.8M Est., Adj EBITDA Of $50M-$60M

Asset Sales

Sun Communities Entered Into Agreement To Sell 100% Interest Of Safe Harbor Marinas To Blackstone Infrastructure For $5.65B

Raymond James analyst Stephen Laws downgrades Arbor Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABR#NYSE">ABR</a>) from Outperform to Market Perform.

Downgrades

Raymond James Downgrades Arbor Realty Trust to Market Perform

Citizens Capital Markets analyst David Turkaly reiterates Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) from Market Perform to Market Perform.

GMED

Citizens Capital Markets Reiterates Market Perform on Globus Medicalto Market Perform

Northland Capital Markets analyst Ted Jackson upgrades Toro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTC#NYSE">TTC</a>) from Market Perform to Outperform and maintains the price target from $100 to $100.

Northland Capital Markets Upgrades Toro to Outperform, Maintains Price Target to $100

On Monday, the FDA declined Invivyd, Inc.&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>)&nbsp;request to expand the existing emergency use authorization (EUA) for pre-exposure prophylaxis of COVID-19 EUA for Pemgarda (pemivibart) for mild-to-moderate COVID-19 in adults and adolescents who have moderate-to-<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43908842/fda-declined-invivyds-request-to-expand-existing-emergency-use-authorization-of-pemgarda-pemivibar" rel="noreferrer noopener">severe immune compromise</a>.
Existing Pemgarda emergency use for pre-exposure prophylaxis of COVID-19 in certain immunocompromised patients remains in effect.
The company said the COVID-19 treatment opportunity for pemivibart was not contemplated in existing financial guidance.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42920654/whats-going-on-with-covid-19-antibody-developer-invivyd-stock-on-friday" rel="noreferrer noopener">What&#8217;s Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?</a>
FDA&#8217;s reasoning appears to center on a belief that COVID-19 treatment immunobridging analyses for a monoclonal antibody (mAb) must meet a standard of superior antiviral activity rather than equivalent antiviral activity to past, highly effective, previously authorized and now inactive COVID-19 mAbs in a bridging analysis of sVNA1&nbsp;titer levels, otherwise the Agency is &#8220;unable to reasonably conclude that the known and potential benefits of pemivibart…outweigh the known and potential risks&#8221;
In the near term, Invivyd plans to share detailed data and regulatory correspondence regarding pemivibart, VYD2311, and the immunobridging of COVID-19 antibodies.
Earlier this month,&nbsp;Invivyd released new data from the <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43438525/invivyd-touts-encouraging-data-from-covid-19-antibody-trial-stock-jumps" rel="noreferrer noopener">ongoing Phase 1/2 trial of VYD2311</a>.
As of Day 65, serum concentrations remain high, potentially substantially increasing the observed half-life of VYD2311 relative to pemivibart, the company's&nbsp;monoclonal antibody&nbsp;medication authorized for the&nbsp;pre-exposure prophylaxis&nbsp;(prevention) of&nbsp;COVID‑19.
Price Action: IVVD stock is down 29.9% at $1.24&nbsp;during the premarket session on last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/asset-sales/25/02/43909136/equitable-inks-reinsurance-deal-with-rga-and-plans-to-boost-stake-in-alliancebernstein-details" target="_blank" rel="noreferrer noopener">Equitable Inks Reinsurance Deal With RGA And Plans To Boost Stake In AllianceBernstein: Details</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Movers

Trading Ideas

General

IVVD

FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients

Citizens Capital Markets analyst Constantine Davides maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Market Outperform and raises the price target from $12 to $13.

Citizens Capital Markets Maintains Market Outperform on Evolent Health, Raises Price Target to $13

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) just dropped a headline-grabbing $500 billion U.S. investment plan, promising factories, jobs, and <a href="https://www.benzinga.com/tech/25/02/43910982/apple-commits-500-billion-in-us-investment-for-ai-push-boost-us-manufacturing-tech">a whole lot of chipmaking</a>.
While the headlines sound impressive — investors want to know if the stock is ready to rally or fizzle out.
<h2 class="wp-block-heading">Bullish Momentum, But Cracks Are Showing</h2>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022425&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="629" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/24073043/Screenshot-2025-02-24-at-6.00.26-PM.png" alt="" class="wp-image-795273" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/24073043/Screenshot-2025-02-24-at-6.00.26-PM.png 629w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/24073043/Screenshot-2025-02-24-at-6.00.26-PM-300x233.png 300w" sizes="(max-width: 629px) 100vw, 629px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022425&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
From a technical perspective, Apple&#8217;s stock is flashing bullish signals across the board. Trading at $245.55, Apple stock sits comfortably above its five, 20, and 50-day exponential moving averages (EMAs), typically a strong indicator of upward momentum. The eight-day simple moving average (SMA) stands at $242.04, while the 20-day sits at $236.10, both signaling continued bullishness.
The Moving Average Convergence Divergence (MACD) indicator at 2.22 reinforces the positive trend, while the Relative Strength Index (RSI) of 61.17 suggests the stock isn't overbought just yet. 
And with the 200-day SMA trailing far behind at $224.39, Apple's current price remains firmly in bullish territory.
Read Also: <a href="https://www.benzinga.com/tech/25/02/43906680/apples-m4-macbook-air-set-for-march-debut-says-top-analyst-new-13-inch-and-15-inch-models-reportedly-incoming">Apple&#8217;s M4 MacBook Air Set For March Debut, Says Top Analyst — New 13-Inch And 15-Inch Models Reportedly Incoming</a>
<h2 class="wp-block-heading">Selling Pressure Clouds The Picture</h2>
But here's the catch: despite the technical strength, Apple&#8217;s stock is facing noticeable selling pressure. This often hints at a potential cooldown, especially after an extended rally. 
While Apple&#8217;s massive investment plan may provide fundamental support, technical traders will be watching closely for signs of a reversal.
<h2 class="wp-block-heading">Investor Takeaway</h2>
Apple&#8217;s <a href="https://www.apple.com/newsroom/2025/02/apple-will-spend-more-than-500-billion-usd-in-the-us-over-the-next-four-years/">$500 billion splash</a> might make headlines, but the real story lies in the charts. The stock is undeniably bullish for now, but with selling pressure building, chasing the rally without a tight stop could get risky. 
Keep an eye on those moving averages—if Apple stock slips below the 20-day SMA, the bears might finally get their turn.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/02/43906541/alibaba-to-invest-a-massive-53-billion-in-ai-infrastructure-taking-on-trumps-stargate-ai-plan">Alibaba To Invest A Massive $53 Billion In AI Infrastructure, Taking On Trump&#8217;s Stargate AI Plan</a></li>
</ul>
Image: Shutterstock

Technicals

Tech

AAPL

Apple Makes $500 Billion Bet: Is AAPL Stock Ready To Shine Or Stumble?

SBET

SharpLink Gaming Acquires 10% Equity Stake In Armchair Enterprises For $500,000 And Right of First Refusal To Acquire Controlling Interest

Lake Street analyst Brooks O'Neil initiates coverage on Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) with a Buy rating and announces Price Target of $30.

BBNX

Lake Street Initiates Coverage On Beta Bionics with Buy Rating, Announces Price Target of $30

Hovnanian Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOV#NYSE">HOV</a>) reported quarterly earnings of $3.58 per share. This is a 23.02 percent increase over earnings of $2.91 per share from the same period last year. The company reported quarterly sales of $673.62 million which missed the analyst consensus estimate of $705.80 million by 4.56 percent. This is a 13.37 percent increase over sales of $594.20 million the same period last year.

Earnings

Earnings Misses

Hovnanian Enterprises Q1 2025 GAAP EPS $3.58 Up From $2.91 YoY, Sales $673.62M Miss $705.80M Estimate

<ul>
<li>TSLA</li>
<li>NVDA</li>
<li>LUNR</li>
<li>PLTR</li>
<li>SMCI</li>
<li>BABA</li>
<li>GOOGL</li>
<li>NBIS</li>
<li>AAPL</li>
<li>HOOD</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

BABA

GOOGL

HOOD

LUNR

NBIS

NVDA

PLTR

SMCI

TSLA

Top 10 Trending Stocks On WallStreetBets As Of February 24, 2025 (Via Swaggy Stocks)

Company expands multiomics portfolio with new roadmap technologies spanning genomics, spatial, single cell, CRISPR, and methylation, as well as a new multimodal data analysis platform
Built on Illumina's powerful sequencers, new, disruptive omics solutions surpass industry standards for quality, scale, accuracy, and replicability
SAN DIEGO, Feb. 24, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) has unveiled a series of roadmap innovations, establishing the industry's largest portfolio of omics solutions and sequencing applications. The solutions – spanning genomics, spatial transcriptomics, single cell analysis, CRISPR technologies, epigenetics, and data analytics software – will enable researchers to derive breakthrough insights around the drivers of disease. The new omics solutions surpass industry standards for scale, accuracy, and reliability because they are built on Illumina's powerful sequencers, known for unmatched quality, consistency, and accuracy. The expanded multiomics portfolio will be presented today at the Advances in Genome Biology and Technology (AGBT)&nbsp;General Meeting.

ILMN

Illumina Unveils Largest Omics Solutions Portfolio Including Genomics, Spatial, Single Cell, CRISPR Technologies; Introduces Multimodal Data Analysis Platform

In the current market session, Enterprise Prods Partners Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) share price is at $33.50, after a 0.48% spike. Moreover, over the past month, the stock fell by 1.10%, but in the past year, went up by 20.75%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1740406519_0.png" alt="Past Year Chart" />

<h3>Enterprise Prods Partners P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 29.51 in the Oil, Gas &amp; Consumable Fuels industry, Enterprise Prods Partners Inc. has a lower P/E ratio of 12.39. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1740406519_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Comments

Alignment Healthcare

ニュース

最新ニュース Alignment Healthcare (NASDAQ:ALHC) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル